Trends Toward Standardization - Although some aspects of single-use components can be standardized, it is unlikely that any materials or design features will become a commodity - BioPharm


Trends Toward Standardization
Although some aspects of single-use components can be standardized, it is unlikely that any materials or design features will become a commodity

BioPharm International
Volume 24, Issue 2, pp. 23-24


One area that can benefit from a form of standardization is quality agreements. In a recent editorial I wrote for PTE (October 2010; available at, I discussed a new initiative by BPSA to develop a quality agreement template for singleuse suppliers and users. The FDA has provided guidance on establishing quality agreements with contract manufacturers of licensed biologics, and drug manufacturers are seeking similar agreements with all their suppliers, including equipment suppliers.1 The Society of Chemical Manufacturers and Affiliates, home to BPSA, has a Bulk Pharmaceuticals Task Force that has developed a template for quality agreements related to the manufacture and release of substances regulated by the FDA.2 A similar template has been developed by the International Pharmaceutical Consortium on Regulation and Science for use by drug manufacturers and suppliers when addressing raw materials, container closure/device components and packaging materials.3 BPSA, through its Singleuse System Quality Agreement Template Task Force, is adapting the content of these guides to develop a template specific to singleuse manufacturing. This template is intended to simplify and standardize the timeconsuming and sometimes difficult process of negotiating quality agreements between biopharmaceutical or vaccine manufacturers and singleuse system or component suppliers.

To discuss this topic further and provide an opportunity for users and suppliers to offer input, BioPharm and BPSA are collaborating to produce a web seminar on quality agreements for single-use manufacturing. The seminar is scheduled for Wednesday Mar 2, 2011 (7 am PST, 10 am EST, 3 pm GMT, and 4 pm CET). For more details, see:

BPSA also will be hosting its inaugural International SingleUse Summit in Washington DC (Jul 27–29, 2011). The meeting will focus on the future of biopharmaceutical manufacturing, with a specific emphasis on regulatory considerations and perspectives on the effect of healthcare reform on drug markets. Innovations and market drivers affecting the singleuse industry also will be discussed. More information is available at

In my next column, I'll be reporting on global issues, as well as on the implementation of singleuse components, based on participation as a speaker and panelist at several international meetings, including the ISPE Japan Sterile Products Processing Community of Practice in Japan (Feb 17, 2011), the ISPE Aseptic Processing Seminar in Tampa, Florida (Feb 21–22, 2011), and the IBC Biomanufacturing and SingleUse Systems Asia Conference in China (Mar 7–9, 2011).

In the interim, feel free to send me suggestions about topics, issues, and technology that affect your implementation of single-use technology. I look forward to hearing from you.

Jerold Martin is senior VP of global scientific affairs, Biopharmaceuticals, Pall Life Sciences, Port Washington, NY, and chairman of the Board and Technology Committee of the BioProcess Systems Alliance (BPSA), 516.801.9086,


1. US Food and Drug Administration. Guidance for industry. Cooperative manufacturing arrangements for licensed biologics. Rockville, MD; 2008 Nov. Available from:

2. SOCMA BPTF. Manufacturer's quality agreement template. 2010 Apr. Available from:

3. IPAC-RS. Quality agreement template toolkit. 2009 May. Available from:

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here